Have a personal or library account? Click to login
The Evaluation of Efficacy of Pycnogenol® Fractions on Endothelial Dysfunction Cover

The Evaluation of Efficacy of Pycnogenol® Fractions on Endothelial Dysfunction

European Pharmaceutical Journal
Volume 60 (2013): Issue 1 (June 2013)
By: S. Jankyova,  L. Hlavackova,  E. Kralova,  J. Slazneva,  V. Drobna,  P. Zuzik,  F. Drafi,  P. Mucaji and  Eva Racanska  
Open Access
|Jun 2013

References

  1. [1] Belcaro G et al. Investigation of Pycnogenol® in combination with coenzymeQ10 in heart failure patients (NYHA II/III). Panminerva Med. 2010;52(2 Suppl 1):21-5.
  2. [2] Bozdag-Dundar O et al. Synthesis of hypoglycemic activity of some new flavone derivatives. 4th communications: 6 flavonyl- 2,4-thiazolidinediones. Arzneimittelforschung. 2001;51:623- 627. 10.1055/s-0031-1300091
  3. [3] Bucala R, Tracey K., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endotheliumdependent vasodilation in experimental diabetes. J Clin Invest. 1991;87:432-438. 10.1172/JCI115014
  4. [4] Cai H, Harrison, DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87(10):840-4. 10.1161/01.RES.87.10.840
  5. [5] Cesarone MR et al. Improvement of diabetic microangiopathy with pycnogenol: A prospective, controlled study. Angiology. 2006;57(4):431-6. 10.1177/0003319706290318
  6. [6] Cosentino F, Lüscher TF. Endothelial function in coronary artery disease. Cardiologia. 1997;42(12):1221-7.
  7. [7] Chang KS, Stevens WC. Endothelium-dependent increase in vascular sensitivity to phenylephrine in long-term streptozotocin diabetic rat aorta. Br J Pharmacol. 1992;107(4):983–990. 10.1111/j.1476-5381.1992.tb13395.x
  8. [8] Chatterjeea A, Catravas JD. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascular Pharmacology. 2008; 49(4-6):134-140. 10.1016/j.vph.2008.06.008
  9. [9] Cheynier V et al. Size separation of condensed tannins by normal phase high performance liquid chromatography. Methods Enzymol. 1998;299:178–184. 10.1016/S0076-6879(99)99018-3
  10. [10] Choudhary SK et al. Comprehensive Evaluation of Anti-hyperglycemic Activity of Fractionated Momordica charantia Seed Extract in Alloxan-Induced Diabetic Rats. Evid Based Complement Alternat Med. 2012; doi:10.1155/2012/293650 10.1155/2012/293650354152423320026
  11. [11] Cosentino F et al. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation. 1997;96:25. 10.1161/01.CIR.96.1.259236411
  12. [12] Davis BJ et al. Activation of the AMP-Activated Kinase by Antidiabetes Drug Metformin Stimulates Nitric Oxide Synthesis In Vivo by Promoting the Association of Heat Shock Protein 90 and Endothelial Nitric Oxide Synthase. Diabetes. 2006;55:496-505. 10.2337/diabetes.55.02.06.db05-106416443786
  13. [13] Elrod JW et al. Cardiomyocyte-Specific Overexpression of NO Synthase- 3 Protects Against Myocardial Ischemia-Reperfusion Injury. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1517- 1523. 10.1161/01.ATV.0000224324.52466.e616645153
  14. [14] Fitzpatrick DF et al. Endothelium dependent vascular effects of Pycnogenol. Journal of cardiovascular pharmacology. 1998; 32:509–515. 10.1097/00005344-199810000-000019781917
  15. [15] Hamden K et al. Combined vitamins (C and E) and insulin improve oxidative stress and pancreatic and hepatic injury in alloxan diabetic rats. Biomed Pharmacother. 2009;63(2):95-9. 10.1016/j.biopha.2008.02.00118358681
  16. [16] Hlavačková L et al. The Effect of Indapamide on Development of Myocardial Hypertrophy and Fibrosis in L-NAME-Induced Hypertension in Rat. Physiol. Res. 2011;60:845-852. 10.33549/physiolres.93220121995907
  17. [17] Jankyova S et al. Glucose and blood pressure lowering effects of Pycnogenol® are inefficient to prevent prolongation of QT interval in experimental diabetic cardiomyopathy. Pathol Res Pract. 2012;208(8):452-7. 10.1016/j.prp.2012.05.01022749577
  18. [18] Jankyova S et al. Pycnogenol efficiency on glycaemia, motor nerve conduction velocity and markers of oxidative stress in mild type diabetes in rats. Phytother Res. 2009;23(8):1169-74. 10.1002/ptr.277619165752
  19. [19] Jay D, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications. Free radical Biology &Medicine. 2006;40:183-192. 10.1016/j.freeradbiomed.2005.06.01816413400
  20. [20] Kasiviswanath R, Ramesh A, Kumar KE. Hypoglycemic and antihyperglycemic effect of Gmelina asiatica LINN. in normal and in alloxan induced diabetic rats. Biol Pharm Bull. 2005;28(4):729-32. 10.1248/bpb.28.72915802818
  21. [21] Klimas J et al. Pycnogenol improves left ventricular function in streptozotocin-induced diabetic cardiomyopathy in rats. Phytother Res. 2010;24(7):969-74. 10.1002/ptr.301519957251
  22. [22] Kolacek M et al. Effect of natural polyphenols, pycnogenol® on superoxide dismutase and nitric oxide synthase in diabetic rats. Prague Med Rep. 2010;111(4):279-88.
  23. [23] Krenek P et al. Increased expression of endothelial nitric oxide synthase and caveolin-1 in the aorta of rats with isoproterenol- induced cardiac hypertrophy. Can J Physiol Pharmacol. 2006;84(12):1245-50. 10.1139/y06-07317487232
  24. [24] Lin KY et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002;106:987. 10.1161/01.CIR.0000027109.14149.67
  25. [25] Lin LY et al. Up-regulation of the association between heat shock protein 90 and endothelial nitric oxide synthase prevents high glucose-induced apoptosis in human endothelial cells. J Cell Biochem. 2005;94:194–201. 10.1002/jcb.20195
  26. [26] Liu X, Zhou HJ, Rohdewald P. French Maritime Pine Bark Extract Pycnogenol Dose-Dependently Lowers Glucose in Type 2 diabetic Patients. Diabetes Care. 2004;27:893-896. 10.2337/diacare.27.3.839
  27. [27] Maiti R, Das UK, Ghosh D. Attenuation of hyperlycemia and hyperlipidemia in streptozotocin induced diabetic rats by aqueous extract of seed of Tarmarindus indica. Biol Pharm Bull. 2005;28:1172-1176. 10.1248/bpb.28.1172
  28. [28] Maritim A, Sanders RA, Watkins JBIII. Oxidative stress and diabetic complications: A review. J Biochem Mol Toxicol. 2003;17:24-48. 10.1002/jbt.10058
  29. [29] Packer L et al. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free radical biology & medicine. 1999;27:704-724. 10.1016/S0891-5849(99)00090-8
  30. [30] Parveen K et al. Protective effects of Pycnogenol on hyperglycemia- induced oxidative damage in the liver of type 2 diabetic rats. Chem Biol Interact. 2010;186(2):219-27. 10.1016/j.cbi.2010.04.02320433812
  31. [31] Pieper GM et al. Reversal by L-arginine of a dysfunctional arginine/ nitric oxide pathway in the endothelium of the genetic diabetic BB rat. Diabetologia. 1997;40:910. 10.1007/s0012500507679267985
  32. [32] Rosei EA, Rizzoni D. Small artery remodelling in diabetes. J Cell Mol Med. 2010;14(5):1030-6.
  33. [33] Ryan EA, Pick ME, Marceau C. Use of alternative medicines in diabetes mellitus. Diabetic Medicine. 2001;18(3):242–245. 10.1046/j.1464-5491.2001.00450.x11318847
  34. [34] Schäfer A, Högger P. Oligomeric procyanidins of French maritime pine bark extract (Pycnogenol) effectively inhibit alpha-glucosidase. Diabetes Res Clin Pract. 2007;77(1):41-6. 10.1016/j.diabres.2006.10.01117098323
  35. [35] Sekar, D, Sivagnanam K, Subramanian S. Antidiabetic activity of Momordica charantia seeds on streptozotocin induced diabetic rats. Pharmazie. 2004;60:383–387.
  36. [36] Srinivasan S et al. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia. 2004;47:1727. 10.1007/s00125-004-1525-1
  37. [37] Stuard S. et al. Kidney function in metabolic syndrome may be improved with Pycnogenol®. Panminerva Med. 2010;52(2 Suppl 1):27-32.
  38. [38] Virgili F, Kim D, Packer L. Procyanidins extracted from pine bark protect α-tocopherol in ECV 304 endothelial cells challenged by activated RAW 264.7 macrophages: role of nitric oxide and peroxynitrite. FEBS letters. 1998; 431(3):315-318. 10.1016/S0014-5793(98)00778-9
  39. [39] Wang Y, Marsden PA. Nitric oxide synthases: gene structure and regulation. Adv. Pharmacol. 1995;34:71–90.
  40. [40] Zibadi S et al. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutrition Research. 2008; 28(5): 315-320. 10.1016/j.nutres.2008.03.00319083426
DOI: https://doi.org/10.2478/afpuc-2013-0014 | Journal eISSN: 2453-6725
Journal RSS Feed
Language: English
Page range: 7 - 14
Published on: Jun 27, 2013
Published by: Comenius University in Bratislava, Faculty of Pharmacy
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
diabetes,
Pycnogenol® Keywords mixture,
fractions,
oxidative stress,
endothelial dysfunction
Related subjects:
Pharmacy,
Pharmacy, other

© 2013 S. Jankyova, L. Hlavackova, E. Kralova, J. Slazneva, V. Drobna, P. Zuzik, F. Drafi, P. Mucaji, Eva Racanska, published by Comenius University in Bratislava, Faculty of Pharmacy
This work is licensed under the Creative Commons License.

Previous articleVolume 60 (2013): Issue 1 (June 2013)Next article